About Orgenesis
Orgenesis is a company based in Germantown (United States) founded in 2008. Orgenesis has completed 3 acquisitions, including Koligo Therapeutics, MaSTherCell and Tissue Genesis. Orgenesis offers products and services including POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network. Orgenesis operates in a competitive market with competitors including Enlivex Pharmaceuticals, TissueGene, Ori Biotech, Sernova and MaSTherCell, among others.
- Headquarter Germantown, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orgenesis, Inc.
-
Annual Revenue
$530 K (USD)-98.53as on Dec 31, 2023
-
Net Profit
-$55.36 M (USD)-271.82as on Dec 31, 2023
-
EBITDA
-$53.33 M (USD)-858.67as on Dec 31, 2023
-
Latest Funding Round
$2.34 M (USD), Post-IPO
Mar 04, 2024
-
Investors
Metalmark Capital
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Koligo Therapeutics
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Orgenesis
Orgenesis is a publicly listed company on the OTC with ticker symbol ORGS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Orgenesis
Orgenesis offers a comprehensive portfolio of products and services, including POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network.
Provides pathway for affordable cell and gene therapy development.
Integrated system for closed-loop cell therapy production.
Develops and validates gene therapy options for patients.
Automates harmonized therapy manufacturing processes.
Facilitates global partnerships for therapy distribution.
People of Orgenesis
Unlock access to complete
Unlock access to complete
Funding Insights of Orgenesis
Investors in Orgenesis
Orgenesis has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Metalmark Capital and Kodiak Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Metalmark Capital is focused on growth equity investments in middle-market companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Orgenesis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orgenesis
Orgenesis has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Koligo Therapeutics, MaSTherCell and Tissue Genesis.
Investment portfolio details for Orgenesis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of trans-formative cell therapies for treating chronic pancreatitis and Type I diabetes
|
Locked | Locked | 2016 | Locked | |
|
Services for cell therapy development and manufacturing are provided.
|
Locked | Locked | 2011 | Locked | |
|
Stem cell therapeutics for vascular disease
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Orgenesis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Orgenesis
Detailed financials for Orgenesis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orgenesis Comparisons
Peer comparison for Orgenesis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orgenesis
Orgenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enlivex Pharmaceuticals, TissueGene, Ori Biotech, Sernova and MaSTherCell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Autologous and allogeneic cell immunotherapies are developed for autoimmune conditions.
|
|
| Locked | Locked | Locked |
Regenerative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| Locked | Locked | Locked |
Services for cell therapy development and manufacturing are provided.
|
Detailed competitors of Orgenesis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orgenesis
Complete news archive for Orgenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orgenesis
Orgenesis was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Orgenesis is headquartered in Germantown, United States.
Annual revenue of Orgenesis is $530K as on Dec 31, 2023.
Orgenesis was founded in 2008 and is headquartered in Germantown, United States. Operations focus on the biotechnology sector, where cell and gene therapies are developed to address various disorders. The pipeline encompasses treatments such as ORGCAR19 for lymphoma, MOTC for melanoma, RanTop HPV for genital warts and anal dysplasia, Kyslecel for chronic pancreatitis, Cartil-S for osteoarthritis, and additional candidates.
Orgenesis's top competitors include Ori Biotech, Enlivex Pharmaceuticals and MaSTherCell.
Orgenesis offers POCare Platform, Mobile Processing Units and Labs, POCare Therapies, POCare Technology, and POCare Network.
Yes, Orgenesis is publicly traded on OTC under the ticker symbol ORGS.
Orgenesis has made 3 acquisitions, including Koligo Therapeutics, MaSTherCell, and Tissue Genesis.
Orgenesis has 2 investors. Key investors include Metalmark Capital, and Kodiak Capital.
The ticker symbol of Orgenesis is ORGS on OTC.